Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

Immunotherapy With Radiotherapy for Brain Metastases in Patients With NSCLC: NEJ060

Introduction: Immune checkpoint inhibitor (ICI)–based treatment has become standard treatment for patients with advanced NSCLC. We aimed to determine the survival benefit of upfront radiotherapy for brain metastases (BMs) in patients with NSCLC who received ICI alone (ICI-alone) or with chemotherapy...

Full description

Bibliographic Details
Main Authors: Takehiro Tozuka, MD, Yuji Minegishi, MD, PhD, Ou Yamaguchi, MD, PhD, Kana Watanabe, MD, Yukihiro Toi, MD, Ryota Saito, MD, PhD, Yoshiaki Nagai, MD, PhD, Yosuke Tamura, MD, PhD, Tetsuaki Shoji, MD, PhD, Haruka Odagiri, MD, Noriyuki Ebi, MD, Kosuke Sakai, MD, PhD, Nobuhiro Kanaji, MD, PhD, Makoto Izumi, MD, Sayo Soda, MD, PhD, Satoshi Watanabe, MD, PhD, Satoshi Morita, PhD, Kunihiko Kobayashi, MD, PhD, Masahiro Seike, MD, PhD
Format: Article
Language:English
Published: Elsevier 2024-04-01
Series:JTO Clinical and Research Reports
Subjects:
Immunotherapy
Brain metastases
Non–small cell lung cancer
Radiotherapy
Online Access:http://www.sciencedirect.com/science/article/pii/S2666364324000250

Internet

http://www.sciencedirect.com/science/article/pii/S2666364324000250

Similar Items